Effects of fasudil on pulmonary hypertension in clinical practice
Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The presence of PH is associated with worse outcomes, but the efficacy of current therapy is still unsatisfactory. Beca...
Saved in:
| Published in | Pulmonary pharmacology & therapeutics Vol. 46; pp. 54 - 63 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.10.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The presence of PH is associated with worse outcomes, but the efficacy of current therapy is still unsatisfactory. Because Rho-kinase (ROCK) plays an important role in the pathogenesis of PH, the ROCK inhibitor fasudil is expected to contribute to PH treatment. In animal models of PH, fasudil reduced pulmonary artery pressure (PAP) and improved survival. Furthermore, the short-term efficacy and safety of fasudil in the treatment of PH are demonstrated in clinical trials. Both PAP and pulmonary vascular resistance in patients with PH are significantly decreased by intravenous or inhaled fasudil without apparent side effect. However, no clinical trial has assessed the long-term efficacy of fasudil in the treatment of PH. Limited data suggest that the mid-term use of fasudil could improve exercise capacity and reduce in-hospital mortality. We also discuss the combined use of fasudil and other drugs for PH treatment. However, these combinations have not yet been evaluated in a clinical trial. According to animal studies, the combination of fasudil with beraprost or sildenafil shows synergistic effects, whereas the combination of fasudil with bosentan has no additional ameliorating effects on PH development. |
|---|---|
| AbstractList | Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The presence of PH is associated with worse outcomes, but the efficacy of current therapy is still unsatisfactory. Because Rho-kinase (ROCK) plays an important role in the pathogenesis of PH, the ROCK inhibitor fasudil is expected to contribute to PH treatment. In animal models of PH, fasudil reduced pulmonary artery pressure (PAP) and improved survival. Furthermore, the short-term efficacy and safety of fasudil in the treatment of PH are demonstrated in clinical trials. Both PAP and pulmonary vascular resistance in patients with PH are significantly decreased by intravenous or inhaled fasudil without apparent side effect. However, no clinical trial has assessed the long-term efficacy of fasudil in the treatment of PH. Limited data suggest that the mid-term use of fasudil could improve exercise capacity and reduce in-hospital mortality. We also discuss the combined use of fasudil and other drugs for PH treatment. However, these combinations have not yet been evaluated in a clinical trial. According to animal studies, the combination of fasudil with beraprost or sildenafil shows synergistic effects, whereas the combination of fasudil with bosentan has no additional ameliorating effects on PH development. Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The presence of PH is associated with worse outcomes, but the efficacy of current therapy is still unsatisfactory. Because Rho-kinase (ROCK) plays an important role in the pathogenesis of PH, the ROCK inhibitor fasudil is expected to contribute to PH treatment. In animal models of PH, fasudil reduced pulmonary artery pressure (PAP) and improved survival. Furthermore, the short-term efficacy and safety of fasudil in the treatment of PH are demonstrated in clinical trials. Both PAP and pulmonary vascular resistance in patients with PH are significantly decreased by intravenous or inhaled fasudil without apparent side effect. However, no clinical trial has assessed the long-term efficacy of fasudil in the treatment of PH. Limited data suggest that the mid-term use of fasudil could improve exercise capacity and reduce in-hospital mortality. We also discuss the combined use of fasudil and other drugs for PH treatment. However, these combinations have not yet been evaluated in a clinical trial. According to animal studies, the combination of fasudil with beraprost or sildenafil shows synergistic effects, whereas the combination of fasudil with bosentan has no additional ameliorating effects on PH development.Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The presence of PH is associated with worse outcomes, but the efficacy of current therapy is still unsatisfactory. Because Rho-kinase (ROCK) plays an important role in the pathogenesis of PH, the ROCK inhibitor fasudil is expected to contribute to PH treatment. In animal models of PH, fasudil reduced pulmonary artery pressure (PAP) and improved survival. Furthermore, the short-term efficacy and safety of fasudil in the treatment of PH are demonstrated in clinical trials. Both PAP and pulmonary vascular resistance in patients with PH are significantly decreased by intravenous or inhaled fasudil without apparent side effect. However, no clinical trial has assessed the long-term efficacy of fasudil in the treatment of PH. Limited data suggest that the mid-term use of fasudil could improve exercise capacity and reduce in-hospital mortality. We also discuss the combined use of fasudil and other drugs for PH treatment. However, these combinations have not yet been evaluated in a clinical trial. According to animal studies, the combination of fasudil with beraprost or sildenafil shows synergistic effects, whereas the combination of fasudil with bosentan has no additional ameliorating effects on PH development. |
| Author | Zhang, Yiqing Wu, Shangjie |
| Author_xml | – sequence: 1 givenname: Yiqing surname: Zhang fullname: Zhang, Yiqing email: yeetsingchang@foxmail.com organization: Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China – sequence: 2 givenname: Shangjie surname: Wu fullname: Wu, Shangjie email: wushangjie@medmail.com.cn organization: Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28782712$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtr3DAURkVIyGPaP9BF8TIbO3rYepRuQsgLAtkkayFL11RTj-xKcmH-fTRMZpNFspIQ37mX7-gCHYcpAEI_CG4IJvxq3czLnBuKiWiwbDCmR-icdJTWilN1XO5YtXXXMXWGLlJaY4xFy7pTdEalkFQQeo6ub4cBbE7VNFSDSYvzYzWFal7GzRRM3FZ_tjPEDCH58uxDZUcfvDVjNUdjs7fwDZ0MZkzw_f1code725ebh_rp-f7x5vqptq1guXaUl91cdUJKZlrFLOl5p7BjnDvnegGuH_qOUEeEkZz2khAiFCPOMgm2ZSt0uZ87x-nfAinrjU8WxtEEmJakiaJcCUXKthX6-R5d-g04PUe_KV30oXYJyH3AximlCIO2PptcKuZo_KgJ1jvDeq13hvXOsMZSF8MFpR_Qw_RPod97CIqg_x6iTtZDsOB8LPa1m_zn-K8P-OEX_sL2K_gNsh-n0A |
| CitedBy_id | crossref_primary_10_3390_life11070702 crossref_primary_10_1016_j_pupt_2018_04_004 crossref_primary_10_1039_D0LC00605J crossref_primary_10_1016_j_phrs_2024_107082 crossref_primary_10_1080_13543784_2021_1923693 crossref_primary_10_1007_s11033_020_05953_y crossref_primary_10_1016_j_jconrel_2021_04_030 crossref_primary_10_1111_jcmm_16761 crossref_primary_10_1007_s12012_019_09561_6 crossref_primary_10_1093_humrep_deae137 crossref_primary_10_3389_fphys_2020_00634 crossref_primary_10_1111_chd_12764 crossref_primary_10_1177_1074248419829172 crossref_primary_10_1016_j_bcp_2023_115899 crossref_primary_10_3390_ijms22063279 crossref_primary_10_1016_j_molimm_2018_07_027 crossref_primary_10_1016_j_addr_2018_06_003 crossref_primary_10_1016_j_ejmech_2021_113742 crossref_primary_10_1002_jcsm_12923 crossref_primary_10_1007_s00210_023_02720_1 crossref_primary_10_1007_s13311_020_00844_3 crossref_primary_10_3892_mmr_2024_13332 crossref_primary_10_18632_aging_103910 crossref_primary_10_1080_17512433_2024_2404688 crossref_primary_10_1002_jbmr_3760 crossref_primary_10_1016_j_bbrc_2023_149166 crossref_primary_10_1097_MD_0000000000014342 crossref_primary_10_3892_ijmm_2018_3728 crossref_primary_10_1002_adhm_202300252 crossref_primary_10_3390_cells8101262 crossref_primary_10_1016_j_addr_2020_09_001 crossref_primary_10_1093_cvr_cvy023 crossref_primary_10_1111_bph_14919 crossref_primary_10_3390_cells11111733 crossref_primary_10_1016_j_clim_2024_110200 crossref_primary_10_1016_j_lfs_2020_118960 crossref_primary_10_1055_a_1879_3111 crossref_primary_10_3389_fnmol_2019_00264 crossref_primary_10_3390_ijms24065850 crossref_primary_10_1016_j_wnsx_2023_100253 crossref_primary_10_1021_acs_jmedchem_0c01901 crossref_primary_10_3389_fphys_2018_00951 crossref_primary_10_1177_2045894020973559 crossref_primary_10_1089_jamp_2024_0016 crossref_primary_10_1007_s12204_019_2127_x crossref_primary_10_1016_j_radonc_2020_06_021 crossref_primary_10_4165_kapps_60_107 crossref_primary_10_1007_s10557_019_06851_7 crossref_primary_10_1080_26895293_2024_2304349 crossref_primary_10_3390_jpm13101446 crossref_primary_10_1021_acsptsci_4c00432 crossref_primary_10_34067_KID_0000000000000090 crossref_primary_10_1016_j_ejphar_2022_174779 crossref_primary_10_1139_cjpp_2020_0347 crossref_primary_10_1038_s41380_022_01702_8 crossref_primary_10_3389_fcvm_2021_804934 crossref_primary_10_3390_cells10071648 crossref_primary_10_1016_j_bbr_2025_115524 crossref_primary_10_1159_000511911 |
| Cites_doi | 10.1016/j.jacc.2009.04.009 10.1016/j.ijpharm.2014.01.007 10.1016/j.pupt.2013.07.008 10.1164/rccm.201207-1222OC 10.1097/00005344-200211000-00013 10.1016/j.jacc.2013.10.029 10.3760/cma.j.issn.0366-6999.20131801 10.1038/40187 10.1126/science.273.5272.245 10.1016/j.surneu.2006.10.037 10.1183/09031936.00149011 10.1183/09031936.00095211 10.1161/01.ATV.0000145943.19099.a3 10.1159/000360182 10.1152/ajpregu.00177.2015 10.1016/j.pupt.2010.09.001 10.1016/j.healun.2011.11.020 10.1016/S0024-3205(01)01229-2 10.1097/01.fjc.0000248244.64430.4a 10.1172/JCI24838 10.1186/1471-2466-14-45 10.1021/mp500456k 10.5114/aoms.2015.49740 10.1161/01.RES.0000111804.34509.94 10.1038/hr.2015.33 10.1183/09031936.00130209 10.1083/jcb.140.3.647 10.1016/j.ejmech.2013.10.048 10.1007/s40265-014-0333-2 10.1152/ajplung.00050.2003 10.1016/j.jstrokecerebrovasdis.2004.10.006 10.1371/journal.pone.0046303 10.1161/ATVBAHA.113.301357 10.1074/jbc.273.30.18943 10.1016/j.jacc.2013.10.025 10.1016/j.jconrel.2013.01.011 10.1007/s10067-016-3504-6 10.1161/01.RES.0000174287.17953.83 10.1016/j.phrs.2006.10.009 10.1378/chest.14-0862 10.1152/ajplung.00245.2007 10.1038/sj.bjp.0706408 10.1161/HYPERTENSIONAHA.110.157032 10.1016/j.jacc.2015.03.540 10.1177/0091270006293767 10.1016/j.jns.2005.06.003 10.1007/s00441-016-2539-y 10.1016/j.jacc.2013.10.023 10.1136/hrt.2003.029470 10.1183/09031936.00140309 10.1016/j.ccm.2006.11.010 10.1016/S0008-6363(01)00540-5 10.1002/j.1460-2075.1996.tb00539.x 10.1042/bj3510095 10.1016/j.ijcard.2014.09.101 10.1152/ajplung.00234.2007 10.1016/j.jacc.2005.07.047 10.1371/journal.pone.0168101 10.1161/HYPERTENSIONAHA.114.03406 10.1128/MCB.16.10.5313 10.1007/s00210-006-0082-1 10.3171/jns.1992.76.4.0571 10.1161/CIRCULATIONAHA.110.015693 10.4161/sgtp.29846 10.1124/jpet.109.151449 10.1183/13993003.51032-2015 10.1164/rccm.2009111-699OC 10.1093/eurheartj/ehp022 10.1124/pr.115.010595 10.1126/science.279.5350.509 10.1536/ihj.50.513 10.1152/ajpheart.00327.2011 10.1007/s00380-009-1176-8 10.1152/japplphysiol.00533.2010 10.1097/01.fjc.0000151898.65260.6a 10.1161/01.RES.0000093220.90027.D9 10.1152/ajplung.00066.2016 10.1126/science.275.5304.1308 10.1161/CIRCRESAHA.115.306532 10.1159/000346921 10.1164/rccm.200405-637OC 10.2119/molmed.2013.00165 10.1183/09031936.00042107 10.1097/FJC.0b013e3182a3718f 10.1517/14728222.2012.671811 10.1038/pr.2012.177 10.1007/s00246-008-9315-z 10.1097/FJC.0b013e3181593774 10.1097/FJC.0b013e31806befe6 10.1164/rccm.200805-691OC 10.1164/rccm.201001-0123OC 10.1016/j.jpba.2009.12.028 10.1164/rccm.201407-1382OC 10.1074/jbc.270.49.29051 10.1126/science.285.5429.895 10.1161/CIRCULATIONAHA.112.000765 10.1161/01.RES.0000261658.12024.18 10.1097/FJC.0b013e31802df112 10.1021/acs.jmedchem.5b00683 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Ltd Copyright © 2017 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2017 Elsevier Ltd – notice: Copyright © 2017 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.pupt.2017.08.002 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1522-9629 |
| EndPage | 63 |
| ExternalDocumentID | 28782712 10_1016_j_pupt_2017_08_002 S1094553917300597 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ABZDS ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OGGZJ OI- OU. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SDP SES SEW SPCBC SSH SSP SSZ T5K UHS UNMZH XPP Z5R ZMT ZU3 ~G- AACTN AAIAV AATCM ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c473t-d264356957883a493c1b6590d366dddb7edbfb512d17a862b81117931dc38ec43 |
| IEDL.DBID | .~1 |
| ISSN | 1094-5539 1522-9629 |
| IngestDate | Fri Jul 11 05:44:02 EDT 2025 Thu Apr 03 07:08:18 EDT 2025 Tue Jul 01 00:16:31 EDT 2025 Thu Apr 24 23:06:31 EDT 2025 Fri Feb 23 02:34:23 EST 2024 Tue Aug 26 20:37:37 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | PVR/SVR ROCK SAP RHC PVR SVR SaO2 TPR Pulmonary arterial hypertension PASMC SvO2 CI Rho-kinase CO IPAH Pulmonary hypertension Fasudil ET CTD ERA PAH PH CTEPH Qp/Qs PDEI 6MWD CHD PAP MCT |
| Language | English |
| License | Copyright © 2017 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-d264356957883a493c1b6590d366dddb7edbfb512d17a862b81117931dc38ec43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 28782712 |
| PQID | 1926979147 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1926979147 pubmed_primary_28782712 crossref_citationtrail_10_1016_j_pupt_2017_08_002 crossref_primary_10_1016_j_pupt_2017_08_002 elsevier_sciencedirect_doi_10_1016_j_pupt_2017_08_002 elsevier_clinicalkey_doi_10_1016_j_pupt_2017_08_002 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2017 2017-10-00 2017-Oct 20171001 |
| PublicationDateYYYYMMDD | 2017-10-01 |
| PublicationDate_xml | – month: 10 year: 2017 text: October 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Pulmonary pharmacology & therapeutics |
| PublicationTitleAlternate | Pulm Pharmacol Ther |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Uehata, Ishizaki, Satoh, Ono, Kawahara, Morishita (bib30) 1997; 389 Homma, Nagaoka, Morio, Ota, Gebb, Karoor (bib36) 2007; 50 Li, Xia, Yuan, Sun (bib55) 2009; 30 Loirand (bib48) 2015; 67 Nahar, Absar, Gupta, Kotamraju, McMurtry, Oka (bib82) 2014; 11 Galie, Manes, Negro, Palazzini, Bacchi-Reggiani, Branzi (bib16) 2009; 30 Jiang, Wang, Zhao, Jiang, Wu, Peng (bib58) 2014; 177 Satoh, Utsunomiya, Tsurui, Kobayashi, Ikegaki, Sasaki (bib67) 2001; 69 Hanada, Kudo, Kohmura (bib69) 2005; 14 Shahar, Darawsha, Yalonetsky, Lessick, Kapeliovich, Dragu (bib4) 2016 Suzuki, Shibuya, Satoh, Sugimoto, Takakura (bib72) 2007; 68 Jasinska-Stroschein, Owczarek, Luczak, Orszulak-Michalak (bib87) 2013; 91 Nagaoka, Fagan, Gebb, Morris, Suzuki, Shimokawa (bib63) 2005; 171 Jasinska-Stroschein, Owczarek, Soltysiak, Orszulak-Michalak (bib108) 2016; 12 Shimizu, Fukumoto, Tanaka, Satoh, Ikeda, Shimokawa (bib41) 2013; 33 Tuder, Abman, Braun, Capron, Stevens, Thistlethwaite (bib10) 2009; 54 Michelfelder, Becker, Riedlinger, Siegert, Dromann, Yu (bib3) 2017 Feb; 36 Guignabert, Tu, Girerd, Ricard, Huertas, Montani (bib13) 2015; 147 Sauzeau, Rolli-Derkinderen, Lehoux, Loirand, Pacaud (bib90) 2003; 93 Mehari, Alam, Tian, Cuttica, Barnett, Miles (bib6) 2013; 187 Ghofrani, Morrell, Hoeper, Olschewski, Peacock, Barst (bib97) 2010; 182 Antoniu (bib35) 2012; 16 Shibuya, Hirai, Seto, Satoh, Ohtomo (bib73) 2005; 238 Leung, Chen, Manser, Lim (bib22) 1996; 16 Li, Xia, Li, Zhao, Sun (bib47) 2007; 55 Kunieda, Nakanishi, Matsubara, Ohe, Okano, Kondo (bib15) 2009; 50 Nagaoka, Morio, Casanova, Bauer, Gebb, McMurtry (bib78) 2004; 287 Cicha, Schneiderhan-Marra, Yilmaz, Garlichs, Goppelt-Struebe (bib100) 2004; 24 Kojonazarov, Myrzaakhmatova, Sooronbaev, Ishizaki, Aldashev (bib57) 2012; 39 Julian, Olson (bib24) 2014; 5 Elias-Al-Mamun, Satoh, Tanaka, Shimizu, Nergui, Miyata (bib84) 2014; 78 Guilluy, Sauzeau, Rolli-Derkinderen, Guerin, Sagan, Pacaud (bib91) 2005; 146 Abe, Shimokawa, Morikawa, Uwatoku, Oi, Matsumoto (bib42) 2004; 94 Ishizaki, Maekawa, Fujisawa, Okawa, Iwamatsu, Fujita (bib21) 1996; 15 McNamara, Murthy, Kantores, Teixeira, Engelberts, van Vliet (bib77) 2008; 294 Fukumoto, Yamada, Matsubara, Mizoguchi, Uchino, Yao (bib61) 2013; 77 Thenappan, Shah, Rich, Gomberg-Maitland (bib17) 2007; 30 Satoh, Fukumoto, Shimokawa (bib32) 2011; 301 Shi, Wei (bib71) 2013; 62 Gien, Tseng, Seedorf, Roe, Abman (bib93) 2013; 73 McGoon, Benza, Escribano-Subias, Jiang, Miller, Peacock (bib18) 2013; 62 Guilluy, Eddahibi, Agard, Guignabert, Izikki, Tu (bib39) 2009; 179 Dhaliwal, Badejo, Casey, Murthy, Kadowitz (bib65) 2009; 330 Wang, Qu, Chen, Zhou, Wan (bib104) 2016; 11 Matsui, Maeda, Doi, Yonemura, Amano, Kaibuchi (bib28) 1998; 140 Hemnes, Zaiman, Champion (bib92) 2008; 294 Tuder, Marecki, Richter, Fijalkowska, Flores (bib9) 2007; 28 Oka, Homma, Taraseviciene-Stewart, Morris, Kraskauskas, Burns (bib46) 2007; 100 Do e, Fukumoto, Takaki, Tawara, Ohashi, Nakano (bib38) 2009; 73 Wilkins, Ali, Bradlow, Wharton, Taegtmeyer, Rhodes (bib107) 2010; 181 Hoeper, Barst, Bourge, Feldman, Frost, Galie (bib98) 2013; 127 Vanderpool, Kim, Molthen, Chesler (bib62) 2011; 110 Jansa, Jarkovsky, Al-Hiti, Popelova, Ambroz, Zatocil (bib19) 2014; 14 Lopez, Ebensperger, Herrera, Reyes, Calaf, Cabello (bib45) 2016; 310 Davies, Reddy, Caivano, Cohen (bib66) 2000; 351 Jasinska-Stroschein, Owczarek, Plichta, Orszulak-Michalak (bib88) 2014; 93 Shimokawa, Sunamura, Satoh (bib33) 2016; 118 Galie, Humbert, Vachiery, Gibbs, Lang, Torbicki (bib1) 2015 Dec; 46 Simonneau, Gatzoulis, Adatia, Celermajer, Denton, Ghofrani (bib7) 2013; 62 Hall (bib31) 1998; 279 Connolly, Aaronson (bib34) 2011; 24 Schermuly, Dony, Ghofrani, Pullamsetti, Savai, Roth (bib96) 2005; 115 Bei, Hua-Huy, Duong-Quy, Nguyen, Chen, Nicco (bib43) 2013; 26 Garnock-Jones (bib51) 2014; 74 Xiao, Zhu, Wang, Zhang, Cui, Zhang (bib59) 2015; 79 Hyvelin, Howell, Nichol, Costello, Preston, McLoughlin (bib40) 2005; 97 Shimokawa, Hiramori, Iinuma, Hosoda, Kishida, Osada (bib74) 2002; 40 Hayes, Tobias, Mansour, Kirkby, McCoy, Daniels (bib5) 2014; 190 Tawara, Fukumoto, Shimokawa (bib86) 2007; 50 Leung, Manser, Tan, Lim (bib23) 1995; 270 Gien, Tseng, Seedorf, Kuhn, Abman (bib94) 2016; 311 Maekawa, Ishizaki, Boku, Watanabe, Fujita, Iwamatsu (bib27) 1999; 285 Zeng, Xiong, Zhao, Shan, Liu, Xue (bib105) 2012; 40 Ishizaki, Mizuno (bib44) 2015; 2015 Mouchaers, Schalij, de Boer, Postmus, van Hinsbergh, van Nieuw Amerongen (bib85) 2010; 36 Abe, Tawara, Oi, Hizume, Uwatoku, Fukumoto (bib79) 2006; 48 Guan, Xu, Chen, Hu, Ge, Wen (bib52) 2013; 70 Dahal, Kosanovic, Pamarthi, Sydykov, Lai, Kast (bib64) 2010; 36 Gupta, Gupta, Shaik, Mehvar, McMurtry, Oka (bib81) 2013; 167 Nahar, Absar, Patel, Ahsan (bib83) 2014; 464 Sun, Li, Tian, Wu (bib80) 2015; 8 Abe, Morikawa, Hizume, Uwatoku, Oi, Seto (bib89) 2005; 45 Undem, Rios, Maylor, Shimoda (bib95) 2012; 7 Tuder, Archer, Dorfmuller, Erzurum, Guignabert, Michelakis (bib8) 2013; 62 Chen, Lin, Han, Bai, Wen (bib70) 2010; 52 McLaughlin, Shah, Souza, Humbert (bib14) 2015; 65 Fujisawa, Madaule, Ishizaki, Watanabe, Bito, Saito (bib25) 1998; 273 Jiang, Tawara, Abe, Takaki, Fukumoto, Shimokawa (bib76) 2007; 49 Amano, Chihara, Kimura, Fukata, Nakamura, Matsuura (bib29) 1997; 275 Shibuya, Suzuki, Sugita, Saito, Sasaki, Takakura (bib50) 1992; 76 Kawut, Bagiella, Lederer, Shimbo, Horn, Roberts (bib106) 2011; 123 Jiang, Ai, Jiang, Yuan, Liu, Zhao (bib60) 2015; 38 Tuder (bib11) 2017; 367 Fukumoto, Matoba, Ito, Tanaka, Kishi, Hayashidani (bib53) 2005; 91 Pandit, Lloyd, Reynolds, Lawrence, Reynolds, Wehrens (bib37) 2014; 64 Laufs, Kilter, Konkol, Wassmann, Bohm, Nickenig (bib99) 2002; 53 Chen, Nakano, Kimura, Matoba, Iwata, Miyagawa (bib103) 2011; 57 Zhang, Dai, Wu, Chen, Zhao (bib101) 2014; 127 Hinderling, Karara, Tao, Pawula, Wilding, Lu (bib68) 2007; 47 Andersen, Iversen, Kjaergaard, Mortensen, Nielsen-Kudsk, Bendstrup (bib2) 2012; 31 Guerard, Rakotoniaina, Goirand, Rochette, Dumas, Lirussi (bib102) 2006; 373 Crosswhite, Sun (bib12) 2014; 20 Vicari, Chaitman, Keefe, Smith, Chrysant, Tonkon (bib75) 2005; 46 Mueller-Mottet, Stricker, Domenighetti, Azzola, Geiser, Schwerzmann (bib20) 2015; 89 Fujita, Fukumoto, Saji, Sugimura, Demachi, Nawata (bib56) 2010; 25 Kimura, Ito, Amano, Chihara, Fukata, Nakafuku (bib26) 1996; 273 Feng, LoGrasso, Defert, Li (bib49) 2016; 59 Ishikura, Yamada, Ito, Ota, Nakamura, Isaka (bib54) 2006; 70 Mehari (10.1016/j.pupt.2017.08.002_bib6) 2013; 187 Zhang (10.1016/j.pupt.2017.08.002_bib101) 2014; 127 Hoeper (10.1016/j.pupt.2017.08.002_bib98) 2013; 127 Oka (10.1016/j.pupt.2017.08.002_bib46) 2007; 100 Ishizaki (10.1016/j.pupt.2017.08.002_bib21) 1996; 15 Tuder (10.1016/j.pupt.2017.08.002_bib11) 2017; 367 Chen (10.1016/j.pupt.2017.08.002_bib70) 2010; 52 Fujita (10.1016/j.pupt.2017.08.002_bib56) 2010; 25 Elias-Al-Mamun (10.1016/j.pupt.2017.08.002_bib84) 2014; 78 Uehata (10.1016/j.pupt.2017.08.002_bib30) 1997; 389 Jasinska-Stroschein (10.1016/j.pupt.2017.08.002_bib87) 2013; 91 Guignabert (10.1016/j.pupt.2017.08.002_bib13) 2015; 147 Andersen (10.1016/j.pupt.2017.08.002_bib2) 2012; 31 Tuder (10.1016/j.pupt.2017.08.002_bib9) 2007; 28 Guilluy (10.1016/j.pupt.2017.08.002_bib39) 2009; 179 Julian (10.1016/j.pupt.2017.08.002_bib24) 2014; 5 Loirand (10.1016/j.pupt.2017.08.002_bib48) 2015; 67 Guan (10.1016/j.pupt.2017.08.002_bib52) 2013; 70 Fukumoto (10.1016/j.pupt.2017.08.002_bib53) 2005; 91 Guerard (10.1016/j.pupt.2017.08.002_bib102) 2006; 373 Matsui (10.1016/j.pupt.2017.08.002_bib28) 1998; 140 Gien (10.1016/j.pupt.2017.08.002_bib94) 2016; 311 Hemnes (10.1016/j.pupt.2017.08.002_bib92) 2008; 294 McLaughlin (10.1016/j.pupt.2017.08.002_bib14) 2015; 65 Jiang (10.1016/j.pupt.2017.08.002_bib60) 2015; 38 Thenappan (10.1016/j.pupt.2017.08.002_bib17) 2007; 30 Shibuya (10.1016/j.pupt.2017.08.002_bib50) 1992; 76 Ishikura (10.1016/j.pupt.2017.08.002_bib54) 2006; 70 Shimokawa (10.1016/j.pupt.2017.08.002_bib74) 2002; 40 Davies (10.1016/j.pupt.2017.08.002_bib66) 2000; 351 Gupta (10.1016/j.pupt.2017.08.002_bib81) 2013; 167 Antoniu (10.1016/j.pupt.2017.08.002_bib35) 2012; 16 Lopez (10.1016/j.pupt.2017.08.002_bib45) 2016; 310 Simonneau (10.1016/j.pupt.2017.08.002_bib7) 2013; 62 Mouchaers (10.1016/j.pupt.2017.08.002_bib85) 2010; 36 Dhaliwal (10.1016/j.pupt.2017.08.002_bib65) 2009; 330 Hayes (10.1016/j.pupt.2017.08.002_bib5) 2014; 190 Satoh (10.1016/j.pupt.2017.08.002_bib67) 2001; 69 Tuder (10.1016/j.pupt.2017.08.002_bib10) 2009; 54 Michelfelder (10.1016/j.pupt.2017.08.002_bib3) 2017; 36 Pandit (10.1016/j.pupt.2017.08.002_bib37) 2014; 64 McNamara (10.1016/j.pupt.2017.08.002_bib77) 2008; 294 Hyvelin (10.1016/j.pupt.2017.08.002_bib40) 2005; 97 Li (10.1016/j.pupt.2017.08.002_bib47) 2007; 55 Schermuly (10.1016/j.pupt.2017.08.002_bib96) 2005; 115 Feng (10.1016/j.pupt.2017.08.002_bib49) 2016; 59 Undem (10.1016/j.pupt.2017.08.002_bib95) 2012; 7 Kawut (10.1016/j.pupt.2017.08.002_bib106) 2011; 123 Tawara (10.1016/j.pupt.2017.08.002_bib86) 2007; 50 Kojonazarov (10.1016/j.pupt.2017.08.002_bib57) 2012; 39 Abe (10.1016/j.pupt.2017.08.002_bib79) 2006; 48 Shibuya (10.1016/j.pupt.2017.08.002_bib73) 2005; 238 Homma (10.1016/j.pupt.2017.08.002_bib36) 2007; 50 Ishizaki (10.1016/j.pupt.2017.08.002_bib44) 2015; 2015 Maekawa (10.1016/j.pupt.2017.08.002_bib27) 1999; 285 Guilluy (10.1016/j.pupt.2017.08.002_bib91) 2005; 146 Jasinska-Stroschein (10.1016/j.pupt.2017.08.002_bib88) 2014; 93 Jiang (10.1016/j.pupt.2017.08.002_bib58) 2014; 177 Connolly (10.1016/j.pupt.2017.08.002_bib34) 2011; 24 Li (10.1016/j.pupt.2017.08.002_bib55) 2009; 30 Shimizu (10.1016/j.pupt.2017.08.002_bib41) 2013; 33 Amano (10.1016/j.pupt.2017.08.002_bib29) 1997; 275 Laufs (10.1016/j.pupt.2017.08.002_bib99) 2002; 53 Zeng (10.1016/j.pupt.2017.08.002_bib105) 2012; 40 Galie (10.1016/j.pupt.2017.08.002_bib16) 2009; 30 Shimokawa (10.1016/j.pupt.2017.08.002_bib33) 2016; 118 Leung (10.1016/j.pupt.2017.08.002_bib23) 1995; 270 Nahar (10.1016/j.pupt.2017.08.002_bib83) 2014; 464 Tuder (10.1016/j.pupt.2017.08.002_bib8) 2013; 62 Vanderpool (10.1016/j.pupt.2017.08.002_bib62) 2011; 110 Nagaoka (10.1016/j.pupt.2017.08.002_bib63) 2005; 171 Sauzeau (10.1016/j.pupt.2017.08.002_bib90) 2003; 93 Vicari (10.1016/j.pupt.2017.08.002_bib75) 2005; 46 Jiang (10.1016/j.pupt.2017.08.002_bib76) 2007; 49 Mueller-Mottet (10.1016/j.pupt.2017.08.002_bib20) 2015; 89 Jasinska-Stroschein (10.1016/j.pupt.2017.08.002_bib108) 2016; 12 Dahal (10.1016/j.pupt.2017.08.002_bib64) 2010; 36 Gien (10.1016/j.pupt.2017.08.002_bib93) 2013; 73 Do e (10.1016/j.pupt.2017.08.002_bib38) 2009; 73 Nahar (10.1016/j.pupt.2017.08.002_bib82) 2014; 11 Abe (10.1016/j.pupt.2017.08.002_bib89) 2005; 45 Crosswhite (10.1016/j.pupt.2017.08.002_bib12) 2014; 20 Wilkins (10.1016/j.pupt.2017.08.002_bib107) 2010; 181 Wang (10.1016/j.pupt.2017.08.002_bib104) 2016; 11 Galie (10.1016/j.pupt.2017.08.002_bib1) 2015; 46 Hinderling (10.1016/j.pupt.2017.08.002_bib68) 2007; 47 Suzuki (10.1016/j.pupt.2017.08.002_bib72) 2007; 68 Nagaoka (10.1016/j.pupt.2017.08.002_bib78) 2004; 287 Shahar (10.1016/j.pupt.2017.08.002_bib4) 2016 Kimura (10.1016/j.pupt.2017.08.002_bib26) 1996; 273 Shi (10.1016/j.pupt.2017.08.002_bib71) 2013; 62 Sun (10.1016/j.pupt.2017.08.002_bib80) 2015; 8 Chen (10.1016/j.pupt.2017.08.002_bib103) 2011; 57 Kunieda (10.1016/j.pupt.2017.08.002_bib15) 2009; 50 Hanada (10.1016/j.pupt.2017.08.002_bib69) 2005; 14 Garnock-Jones (10.1016/j.pupt.2017.08.002_bib51) 2014; 74 Fujisawa (10.1016/j.pupt.2017.08.002_bib25) 1998; 273 Bei (10.1016/j.pupt.2017.08.002_bib43) 2013; 26 Jansa (10.1016/j.pupt.2017.08.002_bib19) 2014; 14 McGoon (10.1016/j.pupt.2017.08.002_bib18) 2013; 62 Satoh (10.1016/j.pupt.2017.08.002_bib32) 2011; 301 Ghofrani (10.1016/j.pupt.2017.08.002_bib97) 2010; 182 Xiao (10.1016/j.pupt.2017.08.002_bib59) 2015; 79 Fukumoto (10.1016/j.pupt.2017.08.002_bib61) 2013; 77 Cicha (10.1016/j.pupt.2017.08.002_bib100) 2004; 24 Abe (10.1016/j.pupt.2017.08.002_bib42) 2004; 94 Leung (10.1016/j.pupt.2017.08.002_bib22) 1996; 16 Hall (10.1016/j.pupt.2017.08.002_bib31) 1998; 279 |
| References_xml | – volume: 62 start-page: D4 year: 2013 end-page: D12 ident: bib8 article-title: Relevant issues in the pathology and pathobiology of pulmonary hypertension publication-title: J. Am. Coll. Cardiol. – volume: 67 start-page: 1074 year: 2015 end-page: 1095 ident: bib48 article-title: Rho kinases in health and disease: from basic science to translational research publication-title: Pharmacol. Rev. – volume: 311 start-page: L1090 year: 2016 end-page: L1100 ident: bib94 article-title: Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. – volume: 273 start-page: 18943 year: 1998 end-page: 18949 ident: bib25 article-title: Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules publication-title: J. Biol. Chem. – volume: 50 start-page: 195 year: 2007 end-page: 200 ident: bib86 article-title: Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats publication-title: J. Cardiovasc. Pharmacol. – volume: 123 start-page: 2985 year: 2011 end-page: 2993 ident: bib106 article-title: Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT publication-title: Circulation – volume: 294 start-page: L24 year: 2008 end-page: L33 ident: bib92 article-title: PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. – volume: 30 start-page: 1103 year: 2007 end-page: 1110 ident: bib17 article-title: A USA-based registry for pulmonary arterial hypertension: 1982-2006 publication-title: Eur. Respir. J. – volume: 26 start-page: 635 year: 2013 end-page: 643 ident: bib43 article-title: Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation publication-title: Pulm. Pharmacol. Ther. – volume: 238 start-page: 31 year: 2005 end-page: 39 ident: bib73 article-title: Fasudil Ischemic Stroke Study G. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial publication-title: J. Neurol. Sci. – volume: 14 start-page: 47 year: 2005 end-page: 49 ident: bib69 article-title: Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage publication-title: J. stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. – volume: 373 start-page: 401 year: 2006 end-page: 414 ident: bib102 article-title: The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS publication-title: Naunyn-Schmiedeberg's Archives Pharmacol. – volume: 50 start-page: 697 year: 2007 end-page: 702 ident: bib36 article-title: Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation publication-title: J. Cardiovasc. Pharmacol. – volume: 127 start-page: 869 year: 2014 end-page: 872 ident: bib101 article-title: Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-kappaB activation in hypoxic pulmonary hypertensive rats publication-title: Chin. Med. J. – volume: 31 start-page: 373 year: 2012 end-page: 380 ident: bib2 article-title: Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease publication-title: J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. – volume: 187 start-page: 840 year: 2013 end-page: 847 ident: bib6 article-title: Hemodynamic predictors of mortality in adults with sickle cell disease publication-title: Am. J. Respir. Crit. Care Med. – start-page: 5 year: 2016 ident: bib4 article-title: Time dependence of the effect of right ventricular dysfunction on clinical outcomes after myocardial infarction: role of pulmonary hypertension publication-title: J. Am. Heart Assoc. – volume: 36 start-page: 800 year: 2010 end-page: 807 ident: bib85 article-title: Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil publication-title: Eur. Respir. J. – volume: 15 start-page: 1885 year: 1996 end-page: 1893 ident: bib21 article-title: The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase publication-title: EMBO J. – volume: 7 start-page: e46303 year: 2012 ident: bib95 article-title: Endothelin-1 augments Na(+)/H(+) exchange activity in murine pulmonary arterial smooth muscle cells via Rho kinase publication-title: PLoS One – volume: 14 start-page: 45 year: 2014 ident: bib19 article-title: Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry publication-title: BMC Pulm. Med. – volume: 40 start-page: 67 year: 2012 end-page: 74 ident: bib105 article-title: Atorvastatin in pulmonary arterial hypertension (APATH) study publication-title: Eur. Respir. J. – volume: 270 start-page: 29051 year: 1995 end-page: 29054 ident: bib23 article-title: A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes publication-title: J. Biol. Chem. – volume: 294 start-page: L205 year: 2008 end-page: L213 ident: bib77 article-title: Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. – volume: 16 start-page: 355 year: 2012 end-page: 363 ident: bib35 article-title: Targeting RhoA/ROCK pathway in pulmonary arterial hypertension publication-title: Expert Opin. Ther. Targets – volume: 78 start-page: 967 year: 2014 end-page: 976 ident: bib84 article-title: Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 55 start-page: 64 year: 2007 end-page: 71 ident: bib47 article-title: Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats publication-title: Pharmacol. Res. – volume: 74 start-page: 2211 year: 2014 end-page: 2215 ident: bib51 article-title: Ripasudil: first global approval publication-title: Drugs – volume: 8 start-page: 9517 year: 2015 end-page: 9521 ident: bib80 article-title: Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats publication-title: Int. J. Clin. Exp. Pathol. – volume: 171 start-page: 494 year: 2005 end-page: 499 ident: bib63 article-title: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension publication-title: Am. J. Respir. Crit. Care Med. – volume: 52 start-page: 242 year: 2010 end-page: 248 ident: bib70 article-title: Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry publication-title: J. Pharm. Biomed. Anal. – volume: 91 start-page: 391 year: 2005 end-page: 392 ident: bib53 article-title: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension publication-title: Heart – volume: 181 start-page: 1106 year: 2010 end-page: 1113 ident: bib107 article-title: Simvastatin as a treatment for pulmonary hypertension trial publication-title: Am. J. Respir. Crit. Care Med. – volume: 190 start-page: 898 year: 2014 end-page: 905 ident: bib5 article-title: Pulmonary hypertension in cystic fibrosis with advanced lung disease publication-title: Am. J. Respir. Crit. Care Med. – volume: 140 start-page: 647 year: 1998 end-page: 657 ident: bib28 article-title: Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association publication-title: J. Cell Biol. – volume: 93 start-page: 145 year: 2014 end-page: 150 ident: bib88 article-title: Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension publication-title: Pharmacology – volume: 91 start-page: 178 year: 2013 end-page: 184 ident: bib87 article-title: The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study publication-title: Pharmacology – volume: 89 start-page: 127 year: 2015 end-page: 140 ident: bib20 article-title: Long-term data from the Swiss pulmonary hypertension registry publication-title: Respir. Int. Rev. Thorac. Dis. – volume: 273 start-page: 245 year: 1996 end-page: 248 ident: bib26 article-title: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) publication-title: Science – volume: 118 start-page: 352 year: 2016 end-page: 366 ident: bib33 article-title: RhoA/Rho-kinase in the cardiovascular system publication-title: Circ. Res. – volume: 73 start-page: 1731 year: 2009 end-page: 1739 ident: bib38 article-title: Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension publication-title: Circ. J Off. J. Jpn. Circ. Soc. – volume: 39 start-page: 496 year: 2012 end-page: 498 ident: bib57 article-title: Effects of fasudil in patients with high-altitude pulmonary hypertension publication-title: Eur. Respir. J. – volume: 110 start-page: 188 year: 2011 end-page: 198 ident: bib62 article-title: Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function publication-title: J. Appl. Physiol. – volume: 68 start-page: 31 year: 2007 end-page: 32 ident: bib72 article-title: A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage publication-title: Surg. Neurol. – volume: 73 start-page: 252 year: 2013 end-page: 262 ident: bib93 article-title: Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep publication-title: Pediatr. Res. – volume: 351 start-page: 95 year: 2000 end-page: 105 ident: bib66 article-title: Specificity and mechanism of action of some commonly used protein kinase inhibitors publication-title: Biochem. J. – volume: 24 start-page: 2046 year: 2004 end-page: 2050 ident: bib100 article-title: Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo publication-title: Arterioscler.Thromb. Vasc. Biol. – volume: 54 start-page: S3 year: 2009 end-page: S9 ident: bib10 article-title: Development and pathology of pulmonary hypertension publication-title: J. Am. Coll. Cardiol. – volume: 115 start-page: 2811 year: 2005 end-page: 2821 ident: bib96 article-title: Reversal of experimental pulmonary hypertension by PDGF inhibition publication-title: J. Clin. Investig. – volume: 25 start-page: 144 year: 2010 end-page: 149 ident: bib56 article-title: Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension publication-title: Heart Ves. – volume: 20 start-page: 191 year: 2014 end-page: 201 ident: bib12 article-title: Molecular mechanisms of pulmonary arterial remodeling publication-title: Mol. Med. – volume: 36 start-page: 381 year: 2017 Feb end-page: 390 ident: bib3 article-title: Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity publication-title: Clin. Rheumatol. – volume: 36 start-page: 808 year: 2010 end-page: 818 ident: bib64 article-title: Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension publication-title: Eur. Respir. J. – volume: 330 start-page: 334 year: 2009 end-page: 341 ident: bib65 article-title: Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1 ,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor publication-title: J. Pharmacol. Exp. Ther. – volume: 76 start-page: 571 year: 1992 end-page: 577 ident: bib50 article-title: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial publication-title: J. Neurosurg. – volume: 147 start-page: 529 year: 2015 end-page: 537 ident: bib13 article-title: New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication publication-title: Chest – volume: 59 start-page: 2269 year: 2016 end-page: 2300 ident: bib49 article-title: Rho kinase (ROCK) inhibitors and their therapeutic potential publication-title: J. Med. Chem. – volume: 77 start-page: 2619 year: 2013 end-page: 2625 ident: bib61 article-title: Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 62 start-page: D51 year: 2013 end-page: D59 ident: bib18 article-title: Pulmonary arterial hypertension: epidemiology and registries publication-title: J. Am. Coll. Cardiol. – volume: 79 start-page: 1342 year: 2015 end-page: 1348 ident: bib59 article-title: Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 30 start-page: 394 year: 2009 end-page: 403 ident: bib16 article-title: A meta-analysis of randomized controlled trials in pulmonary arterial hypertension publication-title: Eur. heart J. – volume: 2015 start-page: 720250 year: 2015 ident: bib44 article-title: Blunted activation of Rho-kinase in yak pulmonary circulation – volume: 275 start-page: 1308 year: 1997 end-page: 1311 ident: bib29 article-title: Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase publication-title: Science – volume: 47 start-page: 19 year: 2007 end-page: 25 ident: bib68 article-title: Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract publication-title: J. Clin. Pharmacol. – volume: 12 start-page: 898 year: 2016 end-page: 905 ident: bib108 article-title: Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension publication-title: Archives Med. Sci. AMS – volume: 70 start-page: 613 year: 2013 end-page: 622 ident: bib52 article-title: Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors publication-title: Eur. J. Med. Chem. – volume: 100 start-page: 923 year: 2007 end-page: 929 ident: bib46 article-title: Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats publication-title: Circ. Res. – volume: 389 start-page: 990 year: 1997 end-page: 994 ident: bib30 article-title: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension publication-title: Nature – volume: 70 start-page: 174 year: 2006 end-page: 178 ident: bib54 article-title: Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 62 start-page: 341 year: 2013 end-page: 354 ident: bib71 article-title: Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil publication-title: J. Cardiovasc. Pharmacol. – volume: 182 start-page: 1171 year: 2010 end-page: 1177 ident: bib97 article-title: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy publication-title: Am. J. Respir. Crit. Care Med. – volume: 40 start-page: 751 year: 2002 end-page: 761 ident: bib74 article-title: Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study publication-title: J. Cardiovasc. Pharmacol. – volume: 65 start-page: 1976 year: 2015 end-page: 1997 ident: bib14 article-title: Management of pulmonary arterial hypertension publication-title: J. Am. Coll. Cardiol. – volume: 93 start-page: 630 year: 2003 end-page: 637 ident: bib90 article-title: Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery publication-title: Circ. Res. – volume: 146 start-page: 1010 year: 2005 end-page: 1018 ident: bib91 article-title: Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension publication-title: Br. J. Pharmacol. – volume: 33 start-page: 2780 year: 2013 end-page: 2791 ident: bib41 article-title: Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice publication-title: Arterioscler.Thromb. Vasc. Biol. – volume: 367 start-page: 643 year: 2017 end-page: 649 ident: bib11 article-title: Pulmonary vascular remodeling in pulmonary hypertension publication-title: Cell tissue Res. – volume: 16 start-page: 5313 year: 1996 end-page: 5327 ident: bib22 article-title: The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton publication-title: Mol. Cell. Biol. – volume: 30 start-page: 363 year: 2009 end-page: 366 ident: bib55 article-title: Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease publication-title: Pediatr. Cardiol. – volume: 45 start-page: 120 year: 2005 end-page: 124 ident: bib89 article-title: Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension publication-title: J. Cardiovasc. Pharmacol. – volume: 179 start-page: 1151 year: 2009 end-page: 1158 ident: bib39 article-title: RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling publication-title: Am. J. Respir. Crit. care Med. – volume: 127 start-page: 1128 year: 2013 end-page: 1138 ident: bib98 article-title: Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study publication-title: Circulation – volume: 49 start-page: 85 year: 2007 end-page: 89 ident: bib76 article-title: Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats publication-title: J. Cardiovasc. Pharmacol. – volume: 62 start-page: D34 year: 2013 end-page: D41 ident: bib7 article-title: Updated clinical classification of pulmonary hypertension publication-title: J. Am. Coll. Cardiol. – volume: 301 start-page: H287 year: 2011 end-page: H296 ident: bib32 article-title: Rho-kinase: important new therapeutic target in cardiovascular diseases publication-title: Am. J. Physiol. Heart Circ. Physiol. – volume: 69 start-page: 1441 year: 2001 end-page: 1453 ident: bib67 article-title: Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage publication-title: Life Sci. – volume: 97 start-page: 185 year: 2005 end-page: 191 ident: bib40 article-title: Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation publication-title: Circ. Res. – volume: 57 start-page: 343 year: 2011 end-page: 350 ident: bib103 article-title: Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension publication-title: Hypertens. (Dallas, Tex 1979) – volume: 279 start-page: 509 year: 1998 end-page: 514 ident: bib31 article-title: Rho GTPases and the actin cytoskeleton publication-title: Science – volume: 177 start-page: 61 year: 2014 end-page: 65 ident: bib58 article-title: Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study publication-title: Int. J. Cardiol. – volume: 46 start-page: 1855 year: 2015 Dec end-page: 1856 ident: bib1 article-title: 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS): endorsed by: association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT) publication-title: Eur. Respir. J. – volume: 287 start-page: L665 year: 2004 end-page: L672 ident: bib78 article-title: Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. – volume: 28 start-page: 23 year: 2007 end-page: 42 ident: bib9 article-title: Pathology of pulmonary hypertension publication-title: Clin. Chest Med. – volume: 38 start-page: 539 year: 2015 end-page: 544 ident: bib60 article-title: Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension publication-title: Hypertens. Res. Off. J. Jpn. Soc. Hypertens. – volume: 285 start-page: 895 year: 1999 end-page: 898 ident: bib27 article-title: Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase publication-title: Science – volume: 24 start-page: 1 year: 2011 end-page: 14 ident: bib34 article-title: Key role of the RhoA/Rho kinase system in pulmonary hypertension publication-title: Pulm. Pharmacol. Ther. – volume: 94 start-page: 385 year: 2004 end-page: 393 ident: bib42 article-title: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats publication-title: Circ. Res. – volume: 167 start-page: 189 year: 2013 end-page: 199 ident: bib81 article-title: Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension publication-title: J. Control. Release Off. J. Control. Release Soc. – volume: 53 start-page: 911 year: 2002 end-page: 920 ident: bib99 article-title: Impact of HMG CoA reductase inhibition on small GTPases in the heart publication-title: Cardiovasc. Res. – volume: 11 start-page: e0168101 year: 2016 ident: bib104 article-title: Statins have No additional benefit for pulmonary hypertension: a meta-analysis of randomized controlled trials publication-title: PLoS One – volume: 46 start-page: 1803 year: 2005 end-page: 1811 ident: bib75 article-title: Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial publication-title: J. Am. Coll. Cardiol. – volume: 64 start-page: 1260 year: 2014 end-page: 1265 ident: bib37 article-title: TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process publication-title: Hypertens. (Dallas, Tex 1979) – volume: 310 start-page: R1053 year: 2016 end-page: R1063 ident: bib45 article-title: Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs publication-title: Am. J. Physiol. Regul. Integr. Comp. Physiol. – volume: 5 start-page: e29846 year: 2014 ident: bib24 article-title: Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions publication-title: Small GTPases – volume: 11 start-page: 4374 year: 2014 end-page: 4384 ident: bib82 article-title: Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension publication-title: Mol. Pharm. – volume: 50 start-page: 513 year: 2009 end-page: 529 ident: bib15 article-title: Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension publication-title: Int. heart J. – volume: 464 start-page: 185 year: 2014 end-page: 195 ident: bib83 article-title: Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature publication-title: Int. J. Pharm. – volume: 48 start-page: 280 year: 2006 end-page: 285 ident: bib79 article-title: Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice publication-title: J. Cardiovasc. Pharmacol. – volume: 54 start-page: S3 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib10 article-title: Development and pathology of pulmonary hypertension publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2009.04.009 – volume: 464 start-page: 185 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib83 article-title: Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2014.01.007 – volume: 26 start-page: 635 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib43 article-title: Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation publication-title: Pulm. Pharmacol. Ther. doi: 10.1016/j.pupt.2013.07.008 – volume: 187 start-page: 840 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib6 article-title: Hemodynamic predictors of mortality in adults with sickle cell disease publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201207-1222OC – volume: 40 start-page: 751 year: 2002 ident: 10.1016/j.pupt.2017.08.002_bib74 article-title: Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/00005344-200211000-00013 – volume: 62 start-page: D34 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib7 article-title: Updated clinical classification of pulmonary hypertension publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2013.10.029 – volume: 127 start-page: 869 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib101 article-title: Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-kappaB activation in hypoxic pulmonary hypertensive rats publication-title: Chin. Med. J. doi: 10.3760/cma.j.issn.0366-6999.20131801 – volume: 389 start-page: 990 year: 1997 ident: 10.1016/j.pupt.2017.08.002_bib30 article-title: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension publication-title: Nature doi: 10.1038/40187 – volume: 273 start-page: 245 year: 1996 ident: 10.1016/j.pupt.2017.08.002_bib26 article-title: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) publication-title: Science doi: 10.1126/science.273.5272.245 – volume: 68 start-page: 31 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib72 article-title: A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage publication-title: Surg. Neurol. doi: 10.1016/j.surneu.2006.10.037 – volume: 40 start-page: 67 year: 2012 ident: 10.1016/j.pupt.2017.08.002_bib105 article-title: Atorvastatin in pulmonary arterial hypertension (APATH) study publication-title: Eur. Respir. J. doi: 10.1183/09031936.00149011 – volume: 39 start-page: 496 year: 2012 ident: 10.1016/j.pupt.2017.08.002_bib57 article-title: Effects of fasudil in patients with high-altitude pulmonary hypertension publication-title: Eur. Respir. J. doi: 10.1183/09031936.00095211 – volume: 2015 start-page: 720250 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib44 article-title: Blunted activation of Rho-kinase in yak pulmonary circulation – volume: 24 start-page: 2046 year: 2004 ident: 10.1016/j.pupt.2017.08.002_bib100 article-title: Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo publication-title: Arterioscler.Thromb. Vasc. Biol. doi: 10.1161/01.ATV.0000145943.19099.a3 – volume: 73 start-page: 1731 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib38 article-title: Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension publication-title: Circ. J Off. J. Jpn. Circ. Soc. – volume: 93 start-page: 145 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib88 article-title: Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension publication-title: Pharmacology doi: 10.1159/000360182 – volume: 310 start-page: R1053 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib45 article-title: Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs publication-title: Am. J. Physiol. Regul. Integr. Comp. Physiol. doi: 10.1152/ajpregu.00177.2015 – volume: 24 start-page: 1 year: 2011 ident: 10.1016/j.pupt.2017.08.002_bib34 article-title: Key role of the RhoA/Rho kinase system in pulmonary hypertension publication-title: Pulm. Pharmacol. Ther. doi: 10.1016/j.pupt.2010.09.001 – volume: 31 start-page: 373 year: 2012 ident: 10.1016/j.pupt.2017.08.002_bib2 article-title: Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease publication-title: J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. doi: 10.1016/j.healun.2011.11.020 – volume: 69 start-page: 1441 year: 2001 ident: 10.1016/j.pupt.2017.08.002_bib67 article-title: Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage publication-title: Life Sci. doi: 10.1016/S0024-3205(01)01229-2 – volume: 48 start-page: 280 year: 2006 ident: 10.1016/j.pupt.2017.08.002_bib79 article-title: Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/01.fjc.0000248244.64430.4a – volume: 77 start-page: 2619 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib61 article-title: Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 115 start-page: 2811 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib96 article-title: Reversal of experimental pulmonary hypertension by PDGF inhibition publication-title: J. Clin. Investig. doi: 10.1172/JCI24838 – volume: 14 start-page: 45 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib19 article-title: Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry publication-title: BMC Pulm. Med. doi: 10.1186/1471-2466-14-45 – volume: 11 start-page: 4374 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib82 article-title: Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension publication-title: Mol. Pharm. doi: 10.1021/mp500456k – volume: 12 start-page: 898 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib108 article-title: Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension publication-title: Archives Med. Sci. AMS doi: 10.5114/aoms.2015.49740 – volume: 94 start-page: 385 year: 2004 ident: 10.1016/j.pupt.2017.08.002_bib42 article-title: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats publication-title: Circ. Res. doi: 10.1161/01.RES.0000111804.34509.94 – volume: 38 start-page: 539 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib60 article-title: Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension publication-title: Hypertens. Res. Off. J. Jpn. Soc. Hypertens. doi: 10.1038/hr.2015.33 – volume: 79 start-page: 1342 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib59 article-title: Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 36 start-page: 800 year: 2010 ident: 10.1016/j.pupt.2017.08.002_bib85 article-title: Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil publication-title: Eur. Respir. J. doi: 10.1183/09031936.00130209 – volume: 140 start-page: 647 year: 1998 ident: 10.1016/j.pupt.2017.08.002_bib28 article-title: Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association publication-title: J. Cell Biol. doi: 10.1083/jcb.140.3.647 – volume: 70 start-page: 613 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib52 article-title: Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2013.10.048 – volume: 74 start-page: 2211 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib51 article-title: Ripasudil: first global approval publication-title: Drugs doi: 10.1007/s40265-014-0333-2 – volume: 287 start-page: L665 year: 2004 ident: 10.1016/j.pupt.2017.08.002_bib78 article-title: Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. doi: 10.1152/ajplung.00050.2003 – volume: 14 start-page: 47 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib69 article-title: Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage publication-title: J. stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. doi: 10.1016/j.jstrokecerebrovasdis.2004.10.006 – volume: 7 start-page: e46303 year: 2012 ident: 10.1016/j.pupt.2017.08.002_bib95 article-title: Endothelin-1 augments Na(+)/H(+) exchange activity in murine pulmonary arterial smooth muscle cells via Rho kinase publication-title: PLoS One doi: 10.1371/journal.pone.0046303 – volume: 33 start-page: 2780 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib41 article-title: Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice publication-title: Arterioscler.Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.113.301357 – volume: 273 start-page: 18943 year: 1998 ident: 10.1016/j.pupt.2017.08.002_bib25 article-title: Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules publication-title: J. Biol. Chem. doi: 10.1074/jbc.273.30.18943 – volume: 62 start-page: D4 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib8 article-title: Relevant issues in the pathology and pathobiology of pulmonary hypertension publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2013.10.025 – volume: 167 start-page: 189 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib81 article-title: Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension publication-title: J. Control. Release Off. J. Control. Release Soc. doi: 10.1016/j.jconrel.2013.01.011 – volume: 36 start-page: 381 issue: 2 year: 2017 ident: 10.1016/j.pupt.2017.08.002_bib3 article-title: Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity publication-title: Clin. Rheumatol. doi: 10.1007/s10067-016-3504-6 – volume: 97 start-page: 185 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib40 article-title: Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation publication-title: Circ. Res. doi: 10.1161/01.RES.0000174287.17953.83 – volume: 55 start-page: 64 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib47 article-title: Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2006.10.009 – volume: 147 start-page: 529 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib13 article-title: New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication publication-title: Chest doi: 10.1378/chest.14-0862 – start-page: 5 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib4 article-title: Time dependence of the effect of right ventricular dysfunction on clinical outcomes after myocardial infarction: role of pulmonary hypertension publication-title: J. Am. Heart Assoc. – volume: 294 start-page: L24 year: 2008 ident: 10.1016/j.pupt.2017.08.002_bib92 article-title: PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. doi: 10.1152/ajplung.00245.2007 – volume: 146 start-page: 1010 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib91 article-title: Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension publication-title: Br. J. Pharmacol. doi: 10.1038/sj.bjp.0706408 – volume: 57 start-page: 343 year: 2011 ident: 10.1016/j.pupt.2017.08.002_bib103 article-title: Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension publication-title: Hypertens. (Dallas, Tex 1979) doi: 10.1161/HYPERTENSIONAHA.110.157032 – volume: 65 start-page: 1976 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib14 article-title: Management of pulmonary arterial hypertension publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2015.03.540 – volume: 47 start-page: 19 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib68 article-title: Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract publication-title: J. Clin. Pharmacol. doi: 10.1177/0091270006293767 – volume: 238 start-page: 31 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib73 article-title: Fasudil Ischemic Stroke Study G. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial publication-title: J. Neurol. Sci. doi: 10.1016/j.jns.2005.06.003 – volume: 367 start-page: 643 year: 2017 ident: 10.1016/j.pupt.2017.08.002_bib11 article-title: Pulmonary vascular remodeling in pulmonary hypertension publication-title: Cell tissue Res. doi: 10.1007/s00441-016-2539-y – volume: 62 start-page: D51 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib18 article-title: Pulmonary arterial hypertension: epidemiology and registries publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2013.10.023 – volume: 91 start-page: 391 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib53 article-title: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension publication-title: Heart doi: 10.1136/hrt.2003.029470 – volume: 36 start-page: 808 year: 2010 ident: 10.1016/j.pupt.2017.08.002_bib64 article-title: Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension publication-title: Eur. Respir. J. doi: 10.1183/09031936.00140309 – volume: 28 start-page: 23 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib9 article-title: Pathology of pulmonary hypertension publication-title: Clin. Chest Med. doi: 10.1016/j.ccm.2006.11.010 – volume: 53 start-page: 911 year: 2002 ident: 10.1016/j.pupt.2017.08.002_bib99 article-title: Impact of HMG CoA reductase inhibition on small GTPases in the heart publication-title: Cardiovasc. Res. doi: 10.1016/S0008-6363(01)00540-5 – volume: 15 start-page: 1885 year: 1996 ident: 10.1016/j.pupt.2017.08.002_bib21 article-title: The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase publication-title: EMBO J. doi: 10.1002/j.1460-2075.1996.tb00539.x – volume: 351 start-page: 95 year: 2000 ident: 10.1016/j.pupt.2017.08.002_bib66 article-title: Specificity and mechanism of action of some commonly used protein kinase inhibitors publication-title: Biochem. J. doi: 10.1042/bj3510095 – volume: 177 start-page: 61 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib58 article-title: Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2014.09.101 – volume: 294 start-page: L205 year: 2008 ident: 10.1016/j.pupt.2017.08.002_bib77 article-title: Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. doi: 10.1152/ajplung.00234.2007 – volume: 46 start-page: 1803 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib75 article-title: Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2005.07.047 – volume: 11 start-page: e0168101 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib104 article-title: Statins have No additional benefit for pulmonary hypertension: a meta-analysis of randomized controlled trials publication-title: PLoS One doi: 10.1371/journal.pone.0168101 – volume: 64 start-page: 1260 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib37 article-title: TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process publication-title: Hypertens. (Dallas, Tex 1979) doi: 10.1161/HYPERTENSIONAHA.114.03406 – volume: 16 start-page: 5313 year: 1996 ident: 10.1016/j.pupt.2017.08.002_bib22 article-title: The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.16.10.5313 – volume: 373 start-page: 401 year: 2006 ident: 10.1016/j.pupt.2017.08.002_bib102 article-title: The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS publication-title: Naunyn-Schmiedeberg's Archives Pharmacol. doi: 10.1007/s00210-006-0082-1 – volume: 76 start-page: 571 year: 1992 ident: 10.1016/j.pupt.2017.08.002_bib50 article-title: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial publication-title: J. Neurosurg. doi: 10.3171/jns.1992.76.4.0571 – volume: 123 start-page: 2985 year: 2011 ident: 10.1016/j.pupt.2017.08.002_bib106 article-title: Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.110.015693 – volume: 5 start-page: e29846 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib24 article-title: Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions publication-title: Small GTPases doi: 10.4161/sgtp.29846 – volume: 330 start-page: 334 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib65 article-title: Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1 ,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.109.151449 – volume: 46 start-page: 1855 issue: 6 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib1 publication-title: Eur. Respir. J. doi: 10.1183/13993003.51032-2015 – volume: 181 start-page: 1106 year: 2010 ident: 10.1016/j.pupt.2017.08.002_bib107 article-title: Simvastatin as a treatment for pulmonary hypertension trial publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.2009111-699OC – volume: 30 start-page: 394 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib16 article-title: A meta-analysis of randomized controlled trials in pulmonary arterial hypertension publication-title: Eur. heart J. doi: 10.1093/eurheartj/ehp022 – volume: 67 start-page: 1074 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib48 article-title: Rho kinases in health and disease: from basic science to translational research publication-title: Pharmacol. Rev. doi: 10.1124/pr.115.010595 – volume: 279 start-page: 509 year: 1998 ident: 10.1016/j.pupt.2017.08.002_bib31 article-title: Rho GTPases and the actin cytoskeleton publication-title: Science doi: 10.1126/science.279.5350.509 – volume: 50 start-page: 513 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib15 article-title: Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension publication-title: Int. heart J. doi: 10.1536/ihj.50.513 – volume: 301 start-page: H287 year: 2011 ident: 10.1016/j.pupt.2017.08.002_bib32 article-title: Rho-kinase: important new therapeutic target in cardiovascular diseases publication-title: Am. J. Physiol. Heart Circ. Physiol. doi: 10.1152/ajpheart.00327.2011 – volume: 25 start-page: 144 year: 2010 ident: 10.1016/j.pupt.2017.08.002_bib56 article-title: Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension publication-title: Heart Ves. doi: 10.1007/s00380-009-1176-8 – volume: 110 start-page: 188 year: 2011 ident: 10.1016/j.pupt.2017.08.002_bib62 article-title: Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function publication-title: J. Appl. Physiol. doi: 10.1152/japplphysiol.00533.2010 – volume: 45 start-page: 120 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib89 article-title: Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/01.fjc.0000151898.65260.6a – volume: 8 start-page: 9517 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib80 article-title: Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats publication-title: Int. J. Clin. Exp. Pathol. – volume: 93 start-page: 630 year: 2003 ident: 10.1016/j.pupt.2017.08.002_bib90 article-title: Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery publication-title: Circ. Res. doi: 10.1161/01.RES.0000093220.90027.D9 – volume: 311 start-page: L1090 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib94 article-title: Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups publication-title: Am. J. Physiol. Lung Cell. Mol. Physiol. doi: 10.1152/ajplung.00066.2016 – volume: 275 start-page: 1308 year: 1997 ident: 10.1016/j.pupt.2017.08.002_bib29 article-title: Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase publication-title: Science doi: 10.1126/science.275.5304.1308 – volume: 118 start-page: 352 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib33 article-title: RhoA/Rho-kinase in the cardiovascular system publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.115.306532 – volume: 91 start-page: 178 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib87 article-title: The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study publication-title: Pharmacology doi: 10.1159/000346921 – volume: 171 start-page: 494 year: 2005 ident: 10.1016/j.pupt.2017.08.002_bib63 article-title: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.200405-637OC – volume: 20 start-page: 191 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib12 article-title: Molecular mechanisms of pulmonary arterial remodeling publication-title: Mol. Med. doi: 10.2119/molmed.2013.00165 – volume: 30 start-page: 1103 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib17 article-title: A USA-based registry for pulmonary arterial hypertension: 1982-2006 publication-title: Eur. Respir. J. doi: 10.1183/09031936.00042107 – volume: 62 start-page: 341 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib71 article-title: Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/FJC.0b013e3182a3718f – volume: 16 start-page: 355 year: 2012 ident: 10.1016/j.pupt.2017.08.002_bib35 article-title: Targeting RhoA/ROCK pathway in pulmonary arterial hypertension publication-title: Expert Opin. Ther. Targets doi: 10.1517/14728222.2012.671811 – volume: 78 start-page: 967 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib84 article-title: Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 73 start-page: 252 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib93 article-title: Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep publication-title: Pediatr. Res. doi: 10.1038/pr.2012.177 – volume: 30 start-page: 363 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib55 article-title: Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease publication-title: Pediatr. Cardiol. doi: 10.1007/s00246-008-9315-z – volume: 70 start-page: 174 year: 2006 ident: 10.1016/j.pupt.2017.08.002_bib54 article-title: Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension publication-title: Circ. J. Off. J. Jpn. Circ. Soc. – volume: 50 start-page: 697 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib36 article-title: Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/FJC.0b013e3181593774 – volume: 50 start-page: 195 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib86 article-title: Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/FJC.0b013e31806befe6 – volume: 179 start-page: 1151 year: 2009 ident: 10.1016/j.pupt.2017.08.002_bib39 article-title: RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling publication-title: Am. J. Respir. Crit. care Med. doi: 10.1164/rccm.200805-691OC – volume: 182 start-page: 1171 year: 2010 ident: 10.1016/j.pupt.2017.08.002_bib97 article-title: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201001-0123OC – volume: 52 start-page: 242 year: 2010 ident: 10.1016/j.pupt.2017.08.002_bib70 article-title: Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2009.12.028 – volume: 190 start-page: 898 year: 2014 ident: 10.1016/j.pupt.2017.08.002_bib5 article-title: Pulmonary hypertension in cystic fibrosis with advanced lung disease publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201407-1382OC – volume: 270 start-page: 29051 year: 1995 ident: 10.1016/j.pupt.2017.08.002_bib23 article-title: A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes publication-title: J. Biol. Chem. doi: 10.1074/jbc.270.49.29051 – volume: 89 start-page: 127 year: 2015 ident: 10.1016/j.pupt.2017.08.002_bib20 article-title: Long-term data from the Swiss pulmonary hypertension registry publication-title: Respir. Int. Rev. Thorac. Dis. – volume: 285 start-page: 895 year: 1999 ident: 10.1016/j.pupt.2017.08.002_bib27 article-title: Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase publication-title: Science doi: 10.1126/science.285.5429.895 – volume: 127 start-page: 1128 year: 2013 ident: 10.1016/j.pupt.2017.08.002_bib98 article-title: Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.000765 – volume: 100 start-page: 923 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib46 article-title: Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats publication-title: Circ. Res. doi: 10.1161/01.RES.0000261658.12024.18 – volume: 49 start-page: 85 year: 2007 ident: 10.1016/j.pupt.2017.08.002_bib76 article-title: Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/FJC.0b013e31802df112 – volume: 59 start-page: 2269 year: 2016 ident: 10.1016/j.pupt.2017.08.002_bib49 article-title: Rho kinase (ROCK) inhibitors and their therapeutic potential publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b00683 |
| SSID | ssj0007435 |
| Score | 2.4105747 |
| SecondaryResourceType | review_article |
| Snippet | Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 54 |
| SubjectTerms | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - adverse effects 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology Animals Disease Models, Animal Drug Synergism Fasudil Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - physiopathology Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacology Pulmonary arterial hypertension Pulmonary hypertension rho-Associated Kinases - antagonists & inhibitors Rho-kinase |
| Title | Effects of fasudil on pulmonary hypertension in clinical practice |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1094553917300597 https://dx.doi.org/10.1016/j.pupt.2017.08.002 https://www.ncbi.nlm.nih.gov/pubmed/28782712 https://www.proquest.com/docview/1926979147 |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEB5CCqWXkqYvJ01QoeTSbGytpJV1NKbBfSSYNoHchB671MWsF9t78CW_vaPVrk0OSaEnsULDitFIM4O--QTwyRdu4AoqEsGMTbjPcc8x5RNqhFXcGOXSUDt8dZ1Nbvm3O3G3B-OuFibAKtuzP57pzWnd9vRbbfar2az_i2JmIgTDfCNQrqtQUc65DFZ-cb-DeaCHFM2Np-JJGN0WzkSMV1VXAU9J5UWEVD7mnB4LPhsndHkAL9vokYziBF_BXl4ewvOr9n78EM6mkYl6c05udoVVq3NyRqY7jurNaxhF1uIVWRSkMKvaz-ZkUZKqnqNZmuWG_Mb8dNmg27F7VpKugpJ0ZVVv4Pbyy814krSvKSSOS7ZOPIY-TGQKt-iQGa6YozYTauBZlnkfWJa9LSz6f0-lwTzHDmmgi2PUOzbMHWdvYb9clPl7IDxPhWWmUNjwQlqTytRbh4tMPbeC94B2atSupRoPL17MdYcp-6OD6nVQvQ7PYA7SHnzeylSRaOPJ0axbHd0pAA89jX7gSSmxlXpgZP-U-9gZgMbdF65UTJkv6pXG-DhTUlEue_AuWsZ29piLDlNJ06P__OsxvAhfETn4AfbXyzo_wQhobU8bEz-FZ6Pxzx_T0H79Prn-C1l9BqU |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFH8aQwIuCMZX-TQS7MKy1rGd1AcOEzB1bJ0m0Um7eXaciKIqjZpGqBf-Kf5BnmOnFYcNCWmnSE5eYr28T_n33gN4Z4tskBVURIJpE3Gbo84xaSOqhZFca5nFrnZ4fJqMzvnXC3GxBb-7WhgHqwy239v01lqHlX7gZr-aTvvfKGYmQjDMN1zLdZkGZOVxvvqJeVv98egz_uT3cXz4ZfJpFIXRAlHGU7aMLMYBTCQS5XXINJcsoyYRcmBZkljrWg5bUxh0hpamGoN-M6SudxqjNmPDPOMM33sLbnM0F25swv6vDa4EXbJoj1glj9z2QqWOB5VVTeUAnDTd9xjOq7zhVdFu6_UOH8D9EK6SA8-Rh7CVlztwZxwO5Hdg98y3vl7tkcmmkqveI7vkbNMUe_UIDnyb5JrMC1LourHTGZmXpGpmqAd6sSLfMSFetHB6XJ6WpCvZJF0d12M4vxEeP4Htcl7mz4DwPBaG6ULihRep0XEaW5OhVFHLjeA9oB0bVRZ6m7sRGzPVgdh-KMd65Viv3NzNQdyDD2uaynf2uPZp1v0d1TEAraxCx3MtlVhT_SXV_6R72wmAQnV3Zzi6zOdNrTAgT2QqKU978NRLxnr3mPwO45TGz__zq2_g7mgyPlEnR6fHL-Ceu-Nhiy9he7lo8lcYfi3N61bcCVzetH79ARZXP3A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+fasudil+on+pulmonary+hypertension+in+clinical+practice&rft.jtitle=Pulmonary+pharmacology+%26+therapeutics&rft.au=Zhang%2C+Yiqing&rft.au=Wu%2C+Shangjie&rft.date=2017-10-01&rft.eissn=1522-9629&rft.volume=46&rft.spage=54&rft_id=info:doi/10.1016%2Fj.pupt.2017.08.002&rft_id=info%3Apmid%2F28782712&rft.externalDocID=28782712 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1094-5539&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1094-5539&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1094-5539&client=summon |